Desidustat

DB16135InvestigationalSmall molecule

Desidustat is under investigation in clinical trial NCT04012957 (Desidustat in the Treatment of Anemia in CKD).

Mechanism: The small molecule hypoxia-inducible factor, desidustat, inhibits the prolyl hydrozylase and stimulates erythropoiesis. It is currently being investigated against anemia of inflammation and COVID-19.
Curator reviewed
Formula / weight: C₁₆H₁₆N₂O₆ · 332.312 g/mol (avg)
Code names: BCP29692 · ZYAN1

Resolves to

Compound

Structure

InChIKeyIKRKQQLJYBAPQT-UHFFFAOYSA-NSMILESOC(=O)CNC(=O)C1=C(O)C2=CC=CC=C2N(OCC2CC2)C1=O

Targets

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with Desidustat, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.